Therapies for Children With Autism Spectrum Disorders

Evidence Table. Therapies for children with ASD (continued)
Study
Inclusion/ Exclusion Baseline
Description Intervention
Criteria/ Population Measures Outcomes
CYBOCS-PDD rated by Hispanic or Latino: 3 (4.6)
SD:
clinician weekly; JAMES SES:
VABS Maladaptive Compliance
administered weekly by Maternal education, n (%): behaviors total: behaviors:
experimenter; ABC-C High school graduate/GED 29.2 ± 9.2 (13-51) G1: 3.67 ± 4.87
rated by teacher; SNAP- or less: 8 (12.1)
G2: 3.67 ± 5.64
IV rated weekly by parent Some college or post-high Motor skills: G3: 4.06 ± 4.55
and teacher
school: 25 (37.9)
Motor skills: G4: 3.94 ± 4.88
Groups:
College/advanced 69.2 ± 17.8 (44-113) G5: 3.47 ± 5.41
G1: Low dose of graduate or professional
G1/G5: P = NS
methylphenidate degree: 33 (50.0)
G2/G5: P = NS
G2: Medium dose of Household income: NR
G3/G5: P = NS
methylphenidate Employed mother, n (%):
G4/G5: P = NS
G3: High dose of
methylphenidate
G4: Best dose of
methylphenidate
G5: Placebo
44 (66.7)
Posey et al., Co-interventions held Employed father, n (%): 59
Regulated
2007*
stable during treatment: (89.4)
affective state:
Jahromi et al., NR
Married, n (%): 53 (80.3)
G1: 8.10 ± 5.18
2009^
Frequency of contact Diagnostic approach:
G2: 6.88 ± 4.86
(continued) during study:
In Study
G3: 6.65 ± 6.03
Nightly phone contact Diagnostic tool/method:
G4: 7.42 ± 5.05
during test dose phase; ADI-R administered to
G5: 7.33 ± 4.86
weekly clinic visits during corroborate the DSM-IV
G1/G5: P = NS
crossover trial; visits at 4 diagnosis of autistic
G2/G5: P = NS
and 8 weeks during disorder based on a clinical
G3/G5: P = NS
continuation phase interview and examination;
G4/G5: P = NS
Concomitant therapies: since ADI-R does not have
Repetitive
NR
specific criteria for Asper-
behavior:†
N enrolled, test dose ger disorder and PDD-
See notes
phase:
NOS, these diagnoses
Problem
Total: 72
followed DSM-IV
behavior:
N randomized, double- Diagnostic category, n
ABC-hyperactivity
blind crossover phase: (%):
subscale score,
Total: 66
Autism: 47 (71.2)
mean ± SD:†
G1: 66
PDD-NOS: 14 (21.2)
Parent-rated:
G2: 66
Aspergers: 5 (7.6)
G1: 23.0 ± 11.29
G3: 50
Other characteristics:
G2: 20.6 ± 10.27
G4: NA
Prior medications, n (%):
G3: 22.1 ± 9.67
G5: 66
Stimulant: 6 (9.1)
G4: 17.2 ± 9.87
N completing double- Alpha-2 adrenergic
G5: 26.0 ± 9.90
blind crossover phase: agonist: 5 (7.6)
G1/G5: P = 0.03
Total: 58
Antipsychotic: 3 (4.6)
(es = 0.29)
N continuing to open SSRI: 3 (4.6)
G2/G5: P < 0.001
label extension phase Other: 4 (6.1)
(es = 0.54)
(responders to
G3/G5: P = 0.003
methylphenidate):
(es = 0.40)
35
G4/G5: P < 0.001
N completing extension
(es = 0.89)
phase:
Teacher-rated:
32
G1: 22.9 ± 12.84
SNAP-IV, parent-rated,
G2: 23.6 ± 12.53
n:*
G3: 20.3 ± 11.94
G1: 62
G4: 20.1 ± 12.40
G2: 63
G5: 26.0 ± 11.66
G3: 47
G1/G5: P = 0.03
C-53